Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

University of Alberta

$35,000.00

Peptide decorated micelle for enhanced delivery of Paclitaxel to multidrug resistant solid tumor.

FY 2008-09

Summary
Breast cancer is a major health concern that affects millions of people globally. Worldwide, it is considered the second most common type of cancer and the fifth most common cause of cancer death. Therefore, an effective treatment to combat that disease is necessary. Paclitaxel is an effective mitotic inhibitor used in breast cancer chemotherapy. However, it has wide range of side effects; some of these side effects are associated with the excipient used in its preparation. Consequently, to enhance the benefit of paclitaxel in the management of breast cancer and to reduce the incidence of side effects, the current project aims to develop a new tumor targeted nano-therapeutic that can specifically deliver the anticancer drug paclitaxel to breast tumor cells with minimal toxicity to the normal cells. We proposed the development of nano-carrier that is: i) tumor seeking; ii) can selectively deliver high doses of paclitaxel, to breast tumor cells through a delivery system guided by the breast cancer targeting peptide p160. The delivery systems will be fabricated from a novel family of biocompatible and biodegradable block copolymers that can self assemble to nanoscopic core/shell structures, namely polymeric micelles, in an aqueous environment. The core will contain the anticancer drug paclitaxel; the shell will have the targeting peptide that will direct the whole nano-carrier to the tumor site. After the formulation being optimized to target the breast cancer cells in culture, it will be tested in selected animal models to insure the biological efficacy and safety. This study will develop a revolutionary safe and effective polymeric paclitaxel formulation, which could potentially treat breast cancer with minimal side effects and therefore increasing the quality of life in cancer patients.
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
184638
Name
Shahin Mostafa H
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Not applicable / Specified
Prcname2
Doctoral Research Awards - A
Projecttitle
Peptide decorated micelle for enhanced delivery of Paclitaxel to multidrug resistant solid tumor.
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$35,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Biomaterials; Breast Cancer; Drug Delivery; Drug Targetting; Nanotechnology; Pharmaceutics; Polymer Characterization; Polymer Therapeutics; Polymeric Micelles
Abstract
Breast cancer is a major health concern that affects millions of people globally. Worldwide, it is considered the second most common type of cancer and the fifth most common cause of cancer death. Therefore, an effective treatment to combat that disease is necessary. Paclitaxel is an effective mitotic inhibitor used in breast cancer chemotherapy. However, it has wide range of side effects; some of these side effects are associated with the excipient used in its preparation. Consequently, to enhance the benefit of paclitaxel in the management of breast cancer and to reduce the incidence of side effects, the current project aims to develop a new tumor targeted nano-therapeutic that can specifically deliver the anticancer drug paclitaxel to breast tumor cells with minimal toxicity to the normal cells. We proposed the development of nano-carrier that is: i) tumor seeking; ii) can selectively deliver high doses of paclitaxel, to breast tumor cells through a delivery system guided by the breast cancer targeting peptide p160. The delivery systems will be fabricated from a novel family of biocompatible and biodegradable block copolymers that can self assemble to nanoscopic core/shell structures, namely polymeric micelles, in an aqueous environment. The core will contain the anticancer drug paclitaxel; the shell will have the targeting peptide that will direct the whole nano-carrier to the tumor site. After the formulation being optimized to target the breast cancer cells in culture, it will be tested in selected animal models to insure the biological efficacy and safety. This study will develop a revolutionary safe and effective polymeric paclitaxel formulation, which could potentially treat breast cancer with minimal side effects and therefore increasing the quality of life in cancer patients.
Competitiondate
200810
Approvedterm2
1 yr 0 mth
Pinamesdelim
Shahin, Mostafa H
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $35,000~ $0~